LA OBESIDAD COMO TEMÁTICA DE SALUD PREVALENTE EN EL PERIODISMO ECONÓMICO: ANÁLISIS DE COBERTURA DE CNBC.

Saved in:

Bibliographic Details
Title:	LA OBESIDAD COMO TEMÁTICA DE SALUD PREVALENTE EN EL PERIODISMO ECONÓMICO: ANÁLISIS DE COBERTURA DE CNBC.
Alternate Title:	The obesity as a prevalent health topic in economic journalism: coverage analysis of CNBC.
Authors:	Amigo Benito, Nieves¹ nieves.amigo@urjc.es
Source:	Revista de Comunicación y Salud. 2025, Vol. 15, p1-19. 19p.
Subjects:	OBESITY, GLUCAGON-like peptide-1 agonists, PHARMACEUTICAL industry, CNBC (Television network), BUSINESS journalism, NOVO Nordisk A/S, ELI Lilly & Co.
Geographic Terms:	UNITED States
Abstract (English):	Introduction: Obesity has gained increasing relevance in the economic sphere, particularly following the emergence in recent years of new and revolutionary drugs, whose impact has been significant for the companies that have introduced them to the market. Methodology: This study conducts an in-depth examination of how the U.S. economic media outlet CNBC reports on obesity as a public health issue, through a content analysis of articles published during the first quarter of 2025. The research adopts a focus that prioritizes newsworthiness within a context characterized by dynamism and constant evolution. Results: The findings reveal that, in CNBC’s coverage, obesity is currently associated with GLP-1 medications and the companies that manufacture them, with two main players dominating the market: the Danish firm Novo Nordisk and the American company Eli Lilly. Discussion: The results indicate that CNBC frames obesity less as a public health problem and more as an economic opportunity linked to the pharmaceutical industry. Its discourse aligns closely with corporate and pharmaceutical interests, contributing to the normalization of the medicalization of the issue. Conclusions: CNBC’s media portrayal of obesity presents a vision of the disease centered on the high business potential of GLP-1 drugs and the interests of the major pharmaceutical companies that develop them, as well as on the competition among these firms to lead the market. This representation contributes to reinforcing a narrative in which the disease is commodified, shifting the focus away from preventive care and toward the efficacy of these new and disruptive medications and the economic gains they generate. [ABSTRACT FROM AUTHOR]
Abstract (Spanish):	Introducción: la obesidad ha cobrado una relevancia creciente en el ámbito económico, especialmente a raíz de la aparición en los últimos años de nuevos y revolucionarios fármacos, cuyo impacto ha sido notable en las compañías que los han introducido en el mercado. Metodología: el presente estudio examina en profundidad el tratamiento informativo que el medio económico estadounidense CNBC otorga a la obesidad como problema de salud pública, mediante un análisis de contenido de los artículos publicados durante el primer trimestre de 2025. La investigación se centra en un enfoque que privilegia la actualidad informativa dentro de un ámbito caracterizado por su dinamismo y evolución constante. Resultados: los resultados revelan que la obesidad, en el tratamiento informativo del medio CNBC, se asocia actualmente con los medicamentos GLP-1 y con las compañías que los producen, destacando dos actores principales en el mercado: la danesa Novo Nordisk y la estadounidense Eli Lilly. Discusión: los resultados evidencian que CNBC enmarca la obesidad no tanto como un problema de salud pública, sino como una oportunidad económica vinculada a la industria farmacéutica. Destaca su discurso alineado con los intereses empresariales y farmacéuticos, que naturaliza la medicalización del problema. Conclusiones: el tratamiento mediático de la obesidad por parte de CNBC proyecta una visión de la enfermedad centrada en el alto potencial de negocio de los fármacos GLP-1 y en los intereses de las grandes farmacéuticas que los desarrollan, así como en la competencia entre ellas por liderar el mercado. Esta representación contribuye a reforzar una narrativa en la que la enfermedad se mercantiliza, desplazando el foco del tratamiento preventivo hacia la eficacia de estos nuevos y disruptivos medicamentos y los beneficios económicos que generan. [ABSTRACT FROM AUTHOR]
	Copyright of Revista de Comunicación y Salud is the property of Instituto Internacional de Comunicacion y Salud and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	MedicLatina

Description
Abstract:	Introduction: Obesity has gained increasing relevance in the economic sphere, particularly following the emergence in recent years of new and revolutionary drugs, whose impact has been significant for the companies that have introduced them to the market. Methodology: This study conducts an in-depth examination of how the U.S. economic media outlet CNBC reports on obesity as a public health issue, through a content analysis of articles published during the first quarter of 2025. The research adopts a focus that prioritizes newsworthiness within a context characterized by dynamism and constant evolution. Results: The findings reveal that, in CNBC’s coverage, obesity is currently associated with GLP-1 medications and the companies that manufacture them, with two main players dominating the market: the Danish firm Novo Nordisk and the American company Eli Lilly. Discussion: The results indicate that CNBC frames obesity less as a public health problem and more as an economic opportunity linked to the pharmaceutical industry. Its discourse aligns closely with corporate and pharmaceutical interests, contributing to the normalization of the medicalization of the issue. Conclusions: CNBC’s media portrayal of obesity presents a vision of the disease centered on the high business potential of GLP-1 drugs and the interests of the major pharmaceutical companies that develop them, as well as on the competition among these firms to lead the market. This representation contributes to reinforcing a narrative in which the disease is commodified, shifting the focus away from preventive care and toward the efficacy of these new and disruptive medications and the economic gains they generate. [ABSTRACT FROM AUTHOR]
ISSN:	21745323
DOI:	10.35669/rcys.2025.15.e387